Posted by Michael Wonder on 04 Apr 2023
PHARMAC seeking feedback on the COVID-19 anti-viral molnupiravir
4 April 2023 - PHARMAC are consulting on the role of molnupiravir in New Zealand’s portfolio of COVID-19 treatments.
The consultation seeks feedback on whether PHARMAC should stop funding the treatment or adjust the eligibility criteria for people who may still be expected to benefit from treatment.
